Welcome to our dedicated page for ATEKWS news (Ticker: ATEKWS), a resource for investors and traders seeking the latest updates and insights on ATEKWS stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ATEKWS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ATEKWS's position in the market.
Athena Technology Acquisition Corp. II (NYSE: ATEK.U, ATEK, ATEK WS) announced the adjournment of its Extension Meeting scheduled for December 16, 2022, to December 21, 2022. This meeting will address the Extension Amendment, which seeks to prolong the time to complete a business combination until September 14, 2023. Shareholders can redeem their shares until December 19, 2022, and are encouraged to vote. The company, led by women executives, is focused on merging or acquiring businesses.
Athena Technology Acquisition Corp. II has successfully closed its initial public offering (IPO) of 25 million units at $10.00 each, generating gross proceeds of $250 million. The units began trading on the NYSE under the ticker 'ATEK.U' on December 10, 2021. This IPO marks Athena's third all-women SPAC initiative, led by founder Isabelle Freidheim, aimed at merging with a technology sector business. Each unit consists of one share of Class A common stock and one-half redeemable warrant, with full warrants exercisable at $11.50 per share. Citigroup served as the sole bookrunner for the offering.
